Schizophrenia 3 - Treatment Resistance

Schizophrenia 4

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Study drug as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)

Schizophrenia 5

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of study drug once daily over 12 week treatment period in patients with Schizophrenia and the effect on cognition and function in schizophrenia.

Bipolar

Forest Lab -- Coming soon

Major Depression 1

A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of study drug for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)

Major Depression 2

A Non-Interventional Study of Subjects using study drug, a Study of Adjunctive Treatment of Major Depressive Disorder